Gynecologic Oncology Highlights
Chicago, IL—Immunotherapy holds promise for the maintenance treatment of late-stage ovarian cancer, according to results of a phase 2 clinical trial. The vaccine, made from the patient’s own tumor cells, was able to prolong recurrence-free survival compared with standard of care.
Chicago, IL—The addition of bevacizumab (Avastin) to standard chemotherapy extended survival in women with platinum-sensitive recurrent ovarian cancer compared with chemotherapy alone in the phase 3 randomized controlled GOG0213 trial. The results were presented at the 2015 Society of Gynecologic Oncology annual meeting.
Chicago, IL—Poly (ADP-ribose) polymerase (PARP) inhibitor maintenance therapy with olaparib (Lynparza) for relapsed, platinum-sensitive ovarian cancer would meet conventional standards of cost-effectiveness only if the drug price decreased by ≥66%, according to a modeling study.
Comprehensive Cancer Center Designation Trumps High Volume as Predictor for Outcomes in Ovarian Cancer
Results 1 - 4 of 4